This affects roughly 1 in 3 people and is particularly common in the first few months
The research on perimenopause and depression is clear: this is a vulnerable period for psychiatric symptoms, including the loss of joy
Semaglutide has strong clinical-trial evidence for chronic weight management, including the STEP 1 trial, which showed clinically relevant weight reduction with weekly semaglutide plus lifestyle intervention
Patients on dual therapy report difficulty distinguishing which medication is causing their symptoms, making dose adjustments nearly impossible
The sooner we identify a pattern, the easier it is to correct
Many of these medications are showing weight-independent benefits, including improvements in kidney, liver, cardiovascular risk, sleep apnea, and joint health that have nothing to do with how much weight is lost